Drug Type TCR-T Cell therapy |
Synonyms- |
Target |
Action modulators |
Mechanism NY-ESO-1 modulators(Cancer/testis antigen 1 modulators), TGF beta receptor modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 23 Jun 2026 | |
| Recurrent ovarian cancer | Phase 2 | United States | 23 Jun 2026 |





